8.6 USD
-0.5 (-5.49%)
Overall QNRX gets a fundamental rating of 1 out of 10. We evaluated QNRX against 525 industry peers in the Biotechnology industry. QNRX may be in some trouble as it scores bad on both profitability and health. QNRX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year QNRX has reported negative net income.
- QNRX had a negative operating cash flow in the past year.
- QNRX had negative earnings in each of the past 5 years.
- In the past 5 years QNRX always reported negative operating cash flow.
1.2 Ratios
- QNRX's Return On Assets of -214.33% is on the low side compared to the rest of the industry. QNRX is outperformed by 88.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -214.33% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-64.59%
ROA(5y)-101.87%
ROE(3y)-126.09%
ROE(5y)-751.54%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for QNRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The number of shares outstanding for QNRX has been increased compared to 1 year ago.
- QNRX has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for QNRX has been reduced compared to a year ago.
2.2 Solvency
- QNRX has an Altman-Z score of -21.16. This is a bad value and indicates that QNRX is not financially healthy and even has some risk of bankruptcy.
- QNRX's Altman-Z score of -21.16 is on the low side compared to the rest of the industry. QNRX is outperformed by 83.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -21.16 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 1.04 indicates that QNRX should not have too much problems paying its short term obligations.
- Looking at the Current ratio, with a value of 1.04, QNRX is doing worse than 85.52% of the companies in the same industry.
- QNRX has a Quick Ratio of 1.04. This is a normal value and indicates that QNRX is financially healthy and should not expect problems in meeting its short term obligations.
- QNRX has a Quick ratio of 1.04. This is amonst the worse of the industry: QNRX underperforms 84.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.04 | ||
| Quick Ratio | 1.04 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 77.61% over the past year.
EPS 1Y (TTM)77.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, QNRX will show a very strong growth in Earnings Per Share. The EPS will grow by 20.76% on average per year.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y78.26%
EPS Next 2Y38.63%
EPS Next 3Y25.85%
EPS Next 5Y20.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- QNRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QNRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- QNRX's earnings are expected to grow with 25.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.63%
EPS Next 3Y25.85%
5. Dividend
5.1 Amount
- No dividends for QNRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
QUOIN PHARMACEUTICALS LT-ADR / QNRX FAQ
What is the ChartMill fundamental rating of QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock?
ChartMill assigns a fundamental rating of 1 / 10 to QNRX.
Can you provide the valuation status for QUOIN PHARMACEUTICALS LT-ADR?
ChartMill assigns a valuation rating of 1 / 10 to QUOIN PHARMACEUTICALS LT-ADR (QNRX). This can be considered as Overvalued.
Can you provide the profitability details for QUOIN PHARMACEUTICALS LT-ADR?
QUOIN PHARMACEUTICALS LT-ADR (QNRX) has a profitability rating of 0 / 10.
Can you provide the financial health for QNRX stock?
The financial health rating of QUOIN PHARMACEUTICALS LT-ADR (QNRX) is 1 / 10.
Can you provide the expected EPS growth for QNRX stock?
The Earnings per Share (EPS) of QUOIN PHARMACEUTICALS LT-ADR (QNRX) is expected to grow by 78.26% in the next year.